カドニリアモブと化学療法は,高度な胃がんの生存を促進し,すべてのPDL1レベルを安全に利用する. Cadonilimab plus chemo boosts survival in advanced stomach cancer, working for all PD-L1 levels with good safety.

臨床試験の第3段階であるCOMPASSION-15では,カドニリマブと化学療法が併用され,前線進行胃癌や胃食道結節癌の全生存期間を大幅に改善し,平均33. 9ヶ月間の追跡調査で死亡リスクが39%低下した. A Phase III trial, COMPASSION-15, found that cadonilimab combined with chemotherapy significantly improved overall survival in first-line advanced gastric or gastroesophageal junction cancer, with a 39% lower risk of death after a median 33.9-month follow-up. PDL1の全てのサブグループに,低又はネガティブな表現をしたものを含め,その効果は見受けられ,その治療は安全性に有利なプロフィールを掲載した. Benefits were seen across all PD-L1 subgroups, including those with low or negative expression, and the treatment showed a favorable safety profile. この薬は中国で承認され,警察L1の状態にかかわらず第一項の選択肢として推奨されている. The drug is now approved in China and recommended as a first-line option regardless of PD-L1 status.